4,573 articles in this topic
Mice lacking the sialyltransferase ST8Sia6 develop spontaneous small bowel immune activation and heightened colitis susceptibility, revealing a new glycosylation-based immune checkpoint.
Researchers identify CD44 as the macrophage receptor for TcdB toxin, revealing a succinylation-driven inflammatory pathway with new therapeutic implications.
A newly identified RNA modification pathway in macrophages fuels deadly cardiac dysfunction during sepsis, and blocking it with a drug reverses the damage.
Scientists reveal that N-glycan 'shields' on small RNAs prevent immune flare-ups—unlocking a new paradigm for autoimmunity and cell death biology.
EEG-based neurofeedback and BCI technologies are emerging as evidence-based tools to restore upper limb function in stroke survivors.
Brain-computer interfaces using EEG and fMRI let depression patients self-regulate neural activity, showing real promise as a non-drug treatment.
A meta-analysis comparing neurofeedback, tDCS, and TMS for adult ADHD finds encouraging signals but no technique yet reaches statistical significance.
BCI technology shows transformative potential for restoring motor function, cognition, and emotional health in stroke survivors.
A landmark screen of 41 psychedelics across 318 receptors reveals surprisingly broad pharmacology with major therapeutic implications.
A single psilocybin dose reshapes cortical connectivity in mice by strengthening perceptual pathways and weakening recurrent loops—driven by acute neural firing.
A 2025 review reveals how synaptic and myelin plasticity changes in the amygdala-hippocampus-prefrontal circuit drive PTSD — and how to reverse them.
New research reveals psilocybin's neuroplasticity effects involve multiple receptor types beyond 5-HT2A, including TrkB, reshaping drug development.
